Top Midday Stories: Trump Vows 100% Tariff on Foreign-Made Films; Buffett to Step Down As Berkshire CEO
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?
Market Chatter: India Offers US Reciprocal Zero Tariffs on Steel, Auto Parts, Pharmaceutical Drugs
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?
Fund Update: SATURNA CAPITAL CORP Added 40,521 Shares of ABBVIE ($ABBV) to Their Portfolio
AbbVie Hits 4-week High
AbbVie Shares Snap Seven-session Gaining Streak
8 Health Care Stocks Whale Activity In Today's Session
30 U.S. Picks Based on Up Vs. Down EPS Revisions and Dividend Payouts
BOTOX Cosmetic (OnabotulinumtoxinA) Continues Its Mission of Empowering Entrepreneurs Through "The Confidence Project"
Netflix, Sherwin-Williams, AbbVie And More On CNBC's 'Final Trades'
FDA Approves AbbVie's Upadacitinib for Giant Cell Arteritis
May's Must-See Financial Events: Apple & Nvidia Earnings, Berkshire Meeting, Interest Rate Decision, and More
Guggenheim Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $216
Allergan Aesthetics Announces Inaugural Allergan Medical Institute (AMI) Training Centers Faculty
Express News | CNBC Halftime Report Final Trades: Netflix, AbbVie, IShares U.S. Industrials, Sherwin-Williams Company
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Buy Alphabet And AbbVie
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $204 to $227
AbbVie Is Maintained at Buy by Guggenheim